Orphan Medical responds to Xyrem "approvable" letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Orphan Medical submits Xyrem (sodium oxybate) NDA amendment Oct. 8 in response to FDA's July 2 "approvable" letter for the narcolepsy treatment. The amendment includes "revisions to product labeling and the risk management program, a safety update of ongoing clinical trials, and respiratory data collected during all night polysomnographic recordings of narcolepsy patients in a trial completed in early 2001," the firm says. The respiratory data were included to "address FDA's concern that Xyrem might have a depressant effect on respiration." The company has agreed to conduct a post-marketing trial on acute exposure in respiratory-compromised patients
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.